ストックスクリーナーアプリを入手
13.48
7.24%
0.91
プレマーケット:
13.42
-0.06
-0.45%
前日終値:
$12.57
開ける：
$12.74
24時間の取引高:
1.49M
Relative Volume:
1.20
時価総額：
$1.31B
収益：
-
当期純損益:
$-44.84M
株価収益率:
-28.68
EPS:
-0.47
ネットキャッシュフロー:
$-44.23M
1週間 パフォーマンス:
+18.66%
1か月 パフォーマンス:
+20.57%
6か月 パフォーマンス:
+27.89%
1年 パフォーマンス:
+122.81%
1日の値動き範囲:
$12.45
$13.50
1週間の範囲:
$11.00
$13.50
52週間の値動き範囲:
$6.04
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
名前
Ars Pharmaceuticals Inc
セクター
電話
858-771-9307
住所
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
13.48 | 1.31B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 繰り返されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | Raymond James | Outperform |
| 2024-03-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | 開始されました | William Blair | Outperform |
| 2022-12-13 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
ARS Pharmaceuticals lays down 2025 objectives for epinephrine nasal spray - MSN
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - The Manila Times
ARS Pharma Launches Free Neffy Nasal Spray Program for U.S. Schools to Combat Allergic Reactions - StockTitan
When (SPRY) Moves Investors should Listen - Stock Traders Daily
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $26.00 - MarketBeat
Raymond James Issues Positive Forecast for ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Analyst Upgrade - MarketBeat
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - MSN
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 7.6% After Analyst Upgrade - MarketBeat
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
ARS Pharmaceuticals shares surge on strong Q4 revenue for allergy spray - Investing.com Canada
ARS Pharmaceuticals (NASDAQ:SPRY) Price Target Raised to $27.00 at Leerink Partners - MarketBeat
ARS Pharmaceuticals Announces Preliminary Fourth Quarter - GlobeNewswire
ARS Pharmaceuticals' Neffy Nasal Spray Hits $7.1M in Sales Since Launch, Targets 80% Insurance Coverage - StockTitan
Barclays PLC Buys 73,127 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells 50,000 Shares of Stock - MarketBeat
Ars pharmaceuticals director Laura Shawver sells $555k in stock By Investing.com - Investing.com Australia
Ars pharmaceuticals director Laura Shawver sells $555k in stock - Investing.com India
ARS Pharmaceuticals files for approval of neffy in Canada, U.K. - Yahoo Finance
ARS Pharma seeks approval for epinephrine spray in Canada and UK - Yahoo Finance
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 2.8%Time to Sell? - MarketBeat
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S - The Manila Times
ARS Pharmaceuticals Files for Approval of neffy® in Canada - GlobeNewswire
ARS Pharma Expands Neffy Nasal Spray to UK & Canada, Targets 98% of Global Epinephrine Market - StockTitan
Top US Growth Companies With Insider Ownership In January 2025 - Simply Wall St
Market Sentiment Around Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Simply Wall St
Barclays PLC Raises Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 3.6%Time to Sell? - MarketBeat
Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green - Yahoo Finance
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $24.00 Average Target Price from Brokerages - MarketBeat
State Street Corp Acquires 193,321 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock By Investing.com - Investing.com Australia
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 4% on Insider Selling - MarketBeat
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies - The Manila Times
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal - GlobeNewswire
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock - Investing.com
Ars Pharmaceuticals CEO sells $1.17 million in stock By Investing.com - Investing.com Canada
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of Stock - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpStill a Buy? - MarketBeat
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
ARS Pharmaceuticals to Present at J.P. Morgan's Prestigious Healthcare Conference - StockTitan
Franklin Resources Inc. Trims Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Insider Sell Alert: Justin Chakma Sells 144,605 Shares of ARS Ph - GuruFocus.com
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) COO Brian Dorsey Sells 25,000 Shares - MarketBeat
Justin Chakma Sells 27,272 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5.5%What's Next? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Ars Pharmaceuticals Inc (SPRY) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):